GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
12 Jun 2019 05:10 PM
RNS
Director/PDMR Shareholding
07 Jun 2019 07:00 AM
RNS
FDA approval for Nucala self-administration
04 Jun 2019 08:00 AM
RNS
CHMP positive on GSK's Nucala self-administration
03 Jun 2019 02:31 PM
RNS
Total Voting Rights
24 May 2019 10:54 AM
RNS
Director/PDMR Shareholding
20 May 2019 01:44 PM
RNS
Director/PDMR Shareholding
13 May 2019 05:44 PM
RNS
Block listing Interim Review
13 May 2019 04:19 PM
RNS
Director/PDMR Shareholding
08 May 2019 06:23 PM
RNS
Result of AGM & GM
02 May 2019 05:07 PM
RNS
Trelegy Ellipta asthma study met primary endpoint
01 May 2019 03:11 PM
RNS
Director/PDMR Shareholding
01 May 2019 02:32 PM
RNS
Total Voting Rights
01 May 2019 12:00 PM
RNS
1st Quarter Results
29 Apr 2019 12:00 PM
RNS
ViiV submits NDA for HIV monthly 2 drug injectable
26 Apr 2019 04:16 PM
RNS
ViiV receives CHMP Positive Opinion for Dovato
16 Apr 2019 05:36 PM
RNS
Director/PDMR Shareholding
16 Apr 2019 05:35 PM
RNS
Director/PDMR Shareholding
16 Apr 2019 05:23 PM
RNS
Director/PDMR Shareholding
16 Apr 2019 05:14 PM
RNS
Director/PDMR Shareholding
15 Apr 2019 02:45 PM
RNS
Director/PDMR Shareholding
12 Apr 2019 04:47 PM
RNS
Director/PDMR Shareholding
12 Apr 2019 04:33 PM
RNS
Director/PDMR Shareholding
11 Apr 2019 05:01 PM
RNS
Director/PDMR Shareholding
09 Apr 2019 07:00 AM
RNS
FDA approves ViiV's two-drug HIV regimen, Dovato
02 Apr 2019 01:00 PM
RNS
Publication of AGM and GM Shareholder Documents
01 Apr 2019 04:36 PM
RNS
Total Voting Rights
28 Mar 2019 04:15 PM
RNS
GSK reporting changes - product sales and IFRS 16
25 Mar 2019 05:02 PM
RNS
Director/PDMR Shareholding
21 Mar 2019 04:00 PM
RNS
GSK announces further positive data from DREAMM-1
19 Mar 2019 05:45 PM
RNS
Data from GARNET study evaluating dostarlimab
18 Mar 2019 07:00 AM
RNS
GSK Annual Report 2018 on Form 20-F
12 Mar 2019 03:19 PM
RNS
Director/PDMR Shareholding
12 Mar 2019 01:00 PM
RNS
Annual Financial Report
11 Mar 2019 06:24 PM
RNS
Director/PDMR Shareholding
08 Mar 2019 07:00 AM
RNS
ViiV positive ph3 data for long acting injectable
05 Mar 2019 05:20 PM
RNS
Director/PDMR Shareholding
01 Mar 2019 10:10 AM
RNS
Total Voting Rights
22 Feb 2019 05:30 PM
RNS
Director/PDMR Shareholding
22 Feb 2019 11:21 AM
RNS
GSK response to SFO Statement
21 Feb 2019 04:37 PM
RNS
Director/PDMR Shareholding
21 Feb 2019 04:15 PM
RNS
Director/PDMR Shareholding
20 Feb 2019 02:44 PM
RNS
Director/PDMR Shareholding
19 Feb 2019 02:26 PM
RNS
Director/PDMR Shareholding
19 Feb 2019 01:53 PM
RNS
Director/PDMR Shareholding Replacement
19 Feb 2019 01:41 PM
RNS
Director/PDMR Shareholding
18 Feb 2019 05:13 PM
RNS
Director/PDMR Shareholding
18 Feb 2019 04:14 PM
RNS
Director/PDMR Shareholding
15 Feb 2019 06:19 PM
RNS
Director/PDMR Shareholding
15 Feb 2019 06:16 PM
RNS
Director/PDMR Shareholding
15 Feb 2019 05:39 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings